Ubs Group Ag Zynerba Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023
SELL
$0.33 - $1.39 $2,040 - $8,594
-6,183 Reduced 23.27%
20,385 $25,000
Q2 2023

Aug 11, 2023
SELL
$0.3 - $0.43 $1,115 - $1,598
-3,718 Reduced 12.28%
26,568 $8,000
Q1 2023

May 12, 2023
SELL
$0.4 - $0.67 $4,693 - $7,861
-11,734 Reduced 27.92%
30,286 $13,000
Q4 2022

Feb 08, 2023
BUY
$0.5 - $0.72 $7,565 - $10,893
15,130 Added 56.27%
42,020 $22,000
Q3 2022

Nov 10, 2022
BUY
$0.87 - $1.36 $1,729 - $2,703
1,988 Added 7.98%
26,890 $20,000
Q2 2022

Aug 10, 2022
SELL
$0.86 - $2.06 $2,338 - $5,601
-2,719 Reduced 9.84%
24,902 $28,000
Q1 2022

May 16, 2022
BUY
$1.83 - $3.02 $29,933 - $49,398
16,357 Added 145.21%
27,621 $56,000
Q4 2021

Feb 14, 2022
BUY
$2.88 - $4.3 $15,822 - $23,624
5,494 Added 95.22%
11,264 $32,000
Q3 2021

Nov 15, 2021
SELL
$3.72 - $5.35 $26,233 - $37,728
-7,052 Reduced 55.0%
5,770 $25,000
Q2 2021

Aug 13, 2021
BUY
$3.83 - $5.98 $31,861 - $49,747
8,319 Added 184.74%
12,822 $68,000
Q1 2021

May 12, 2021
SELL
$3.33 - $8.76 $9,077 - $23,879
-2,726 Reduced 37.71%
4,503 $21,000
Q4 2020

Feb 11, 2021
BUY
$3.27 - $4.64 $4,849 - $6,881
1,483 Added 25.81%
7,229 $23,000
Q3 2020

Nov 12, 2020
BUY
$3.23 - $4.3 $14,583 - $19,414
4,515 Added 366.77%
5,746 $20,000
Q2 2020

Jul 31, 2020
SELL
$3.31 - $6.54 $55,770 - $110,192
-16,849 Reduced 93.19%
1,231 $5,000
Q1 2020

May 01, 2020
SELL
$2.9 - $6.16 $56,593 - $120,212
-19,515 Reduced 51.91%
18,080 $69,000
Q4 2019

Feb 14, 2020
BUY
$5.61 - $8.57 $14,821 - $22,641
2,642 Added 7.56%
37,595 $227,000
Q3 2019

Nov 14, 2019
SELL
$7.56 - $15.44 $89,903 - $183,612
-11,892 Reduced 25.39%
34,953 $264,000
Q2 2019

Aug 14, 2019
BUY
$5.4 - $15.5 $211,253 - $606,375
39,121 Added 506.49%
46,845 $635,000
Q1 2019

May 14, 2019
SELL
$3.6 - $6.22 $17,449 - $30,148
-4,847 Reduced 38.56%
7,724 $42,000
Q4 2018

Feb 14, 2019
BUY
$2.89 - $7.91 $20,201 - $55,290
6,990 Added 125.25%
12,571 $38,000
Q3 2018

Nov 14, 2018
BUY
$5.59 - $10.45 $2,085 - $3,897
373 Added 7.16%
5,581 $46,000
Q2 2018

Aug 14, 2018
SELL
$7.98 - $12.39 $17,755 - $27,567
-2,225 Reduced 29.93%
5,208 $50,000
Q1 2018

May 15, 2018
SELL
$8.49 - $13.46 $2,623 - $4,159
-309 Reduced 3.99%
7,433 $64,000
Q4 2017

Feb 14, 2018
SELL
$8.69 - $14.59 $21,664 - $36,372
-2,493 Reduced 24.36%
7,742 $97,000
Q3 2017

Nov 14, 2017
SELL
$5.73 - $9.44 $23,601 - $38,883
-4,119 Reduced 28.7%
10,235 $86,000
Q2 2017

Aug 14, 2017
BUY
N/A
10,457 Added 268.33%
14,354 $244,000
Q1 2017

Nov 14, 2017
BUY
N/A
3,897
3,897 $78,000

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email